Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
ABSTRACT PSMA PET/CT scan is the standard imaging procedure for biochemical recurrent prostate cancer post-prostatectomy due to its high detection rate at low serum PSA levels. However, existing guidelines for clinical target volume (CTV) in prostate bed salvage external beam radiation therapy (sEBRT) are primarily based on experience-based clinical consensus and have been validated using conventional imaging modalities.
Background: PF-05280586 is being developed as a potential biosimilar to rituximab. Similarity of PF-05280586 to rituximab sourced from the EU and US (rituximab-EU and -US) was assessed using structural, functional, nonclinical pharmacokinetic (PK), tolerability, and toxicity studies, and clinical studies. Methods: Structural similarity was determined by peptide mapping and other analytical methods.
Background: Use of single-agent rituximab may provide a useful alternative to watchful waiting by delaying the time to initiation of chemotherapy in patients with low tumor burden follicular lymphoma (LTB-FL). However, access to biologics like rituximab can be restricted. Biosimilars to rituximab represent a potential opportunity to increase patient access and lower treatment cost.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.